Research
OCRA invests more funds into ovarian cancer research than any other public charity.
Read more about Research Read about groundbreaking OCRA-funded research
OCRA's Mission & Impact
Mission & Impact
Our Mission Statement: Ovarian Cancer Research Alliance is dedicated to curing ovarian cancer while improving treatments by advancing innovative science, promoting preventive measures, and advocating for, educating and supporting anyone affected by gynecologic cancers to ensure the best possible care and outcomes.
Results and Milestones
Numbers tell the story of our impact
- Research and Education Funding
- OCRA’s advocacy efforts have helped secure $3.8 billion in federal research and education funding
- $3.8B
- Invested in Science Innovation
- $140M raised and invested in scientific breakthroughs
- $140M
- Individuals Helped Each Year
- Our programs support more than 95,000 individuals annually
- 110K
For each dollar we spend, 81 cents goes to funding critical research and innovative programs
Advancing Research and Fueling Hope
OCRA has both a laser focus and a panoramic view when it comes to the fight against gynecologic cancers.
Center for Public Policy
OCRA has built a team of passionate, dedicated advocates.
Read more about Center for Public Policy Discover our advocacy impact and get involved
Patient Support
In times of adversity, support becomes a beacon of hope.
Read more about Patient Support Learn about our unique programs
OCRA's History of Impact and Innovation
Ovarian Cancer Research Alliance (OCRA) is the oldest and largest ovarian and gynecologic cancer charity in the world. Since its founding in 1994, OCRA has grown into the leading non-government funder of ovarian and related gynecologic cancer research, investing over $140 million in groundbreaking studies. Through innovative education and advocacy efforts, compassionate support programs, and cross-industry collaboration, OCRA is driving progress and pushing the boundaries of what’s possible to improve outcomes for patients and advance research in its quest for a cure.
Related Topics
New AI Accelerator Grant Captures Health and Science Media Attention
OCRA is excited to see the work fueled by our new AI Accelerator Grant resonating with a broad array of audiences. Since the Global Ovarian Cancer Research Consortium announced the inaugural AI Accelerator Grant on February 19, coverage has appeared across health, science, and business media outlets. The $1 million global research award—with an additional … Continued
The Overview: February 2026
The Global Ovarian Cancer Research Consortium awarded its inaugural AI Accelerator Grant in February—and the announcement has been making waves across health, science, and business media, reflecting widespread interest in what this work could mean for patients. The $1 million global research grant, plus an additional $1 million in compute support from Microsoft’s AI for … Continued
Ovarian Cancer Research Alliance Honors Researchers with 2025 Rosalind Franklin and Schreiber Prizes
Recognizing Advances in Ovarian Cancer Research and Immunotherapy Ovarian Cancer Research Alliance (OCRA) announced today the winners of two prizes recognizing exceptional accomplishments in ovarian cancer research. David Huntsman, MD, FRCPC, FCCMG, was awarded the 2025 Rosalind Franklin Prize for Excellence in Ovarian Cancer Research for his findings that have profoundly impacted the treatment of … Continued